Kimford Meador, AAN 2021: Fetal Antiseizure Medication in Pregnant Women with Epilepsy
It was a great pleasure to meet with Kimford Meador (Stanford University, Stanford, CA, USA) to discuss the effects and use of antiseizure medications during pregnancy, in women with epilepsy.
The abstract entitled: ‘Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the MONEAD Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What is known about the risks to children born to women who use antiseizure medications (ASMs) during pregnancy? (0:16)
- How does pregnancy affect seizure frequency and the need for ASMs? (2:37)
- What is known about the changes in clearance rates of ASMs during pregnancy? (3:40)
Disclosures: Kimford Meador has received grants from NIH/NINDS 2U01-NS038455-11A1, NIH/NINDS R01NS088748-01, Medtronics; Eisai Inc., and Sunovion Pharma; and has been a consultant for the Epilepsy Consortium, Eisai, GW Pharmaceuticals, Medtronics, NeuroPace, Novartis, Supernus, Upsher Smith Labs, UCB Pharma, and Vivus Pharma. Clinical income: EEG procedures and patient care.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Epilepsy
Jacqueline French, AAN 2023: XEN1101, a novel potassium channel modulator for the treatment of focal epilepsy
In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses the needs of adults with focal epilepsy and the mechanisms of action of XEN1101, a novel, potent, selective Kv7.2/7.3 potassium channel. The abstract entitled “XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, […]
Jacqueline French, AAN 2023: X-TOLE phase 2b open-label extension trial of XEN1101 in focal epilepsy – interim data
The randomized, double-blind, placebo-controlled phase IIb study X-TOLE (NCT03796962) is investigating the efficacy of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy. In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses this clinical trial and the outcomes of its open-label extension. The […]
Galia Wilson, Dravet Syndrome UK: DSUK Objectives, directions and support for families and people living with Dravet syndrome
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came together looking for support, resources and information relating to the neurological condition. In this interview, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!